Chief investigator Professor Alan Burnett, from Cardiff Universitys School of Medicine, commented on the findings:
These promising results demonstrate how targeting a protein present in more than 90 per cent of AML patients can boost treatment without excessively increasing side effects.
Although there has been some controversy around the use of GO following its withdrawal in the US two years ago, these results appear extremely promising and suggest no such cause for concern if the appropriate dose is given. Crucially, this represents some of the first progress in treating AML patients of this age group for at least 20 years.
More top news
Police have raided another address in Moss Side as they investigate the Manchester Arena attack.
A band of heavy, thundery showers moves in from northern France this afternoon.
Armed police were out in force as runners competed in the largest public event in the city since Monday's terror attack.